Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005796 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
A Phase 1 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00005796 is a Phase 1 study that has completed, run by Indiana University. The registered enrollment target is 10 participants.
The verdict
NCT00005796, a Phase 1 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Inserting a specific gene into a person's peripheral stem cells may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus gene therapy in treating patients who have CNS tumors.
Interventions
- DRUG vincristine sulfate
- DRUG lomustine
- DRUG procarbazine hydrochloride
- BIOLOGICAL gene therapy
- PROCEDURE filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2000-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005796
The ClinicalTrials.gov registry entry for NCT00005796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which vincristine sulfate is the first listed.
NCT00005796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005796 about?
NCT00005796 is a clinical study titled "Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Inserting a specific gene into a person's peripheral stem cells may improve the body's ability to fight cancer or make the c...
What is the current status of trial NCT00005796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2000-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00005796?
The interventions under investigation include: vincristine sulfate (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG), gene therapy (BIOLOGICAL), filgrastim (PROCEDURE).
Who is sponsoring clinical trial NCT00005796?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.